EGA meeting: Governments must make generic medicines markets more competitive
This article was originally published in Scrip
The European generic medicines market is still not as competitive as it could be, and healthcare systems are therefore missing out on important savings, argues a recent survey of the generics industry.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.